On the other hand, in patients with advanced HCC treated with Sorafenib, early Alpha 1 foetoprotein (AFP) increase can serve as a predictive biomarker of disease progression and poor overall and progression-free survival (OS and PFS) (Nakazawa et al., 2013). This evidence concerns the gene AFP and hepatocellular carcinoma.